Rituximab is often used as a steroid-sparing option when patients are poor candidates for corticosteroids (eg, those with uncontrolled diabetes), and can be used to induce or maintain remission when patients do not tolerate corticosteroid tapering, or experience disease recurrence within 12 months of stopping corticosteroids.